James D. Koropatnick

London, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.

Journal: Frontiers in immunology

Published: July 11, 2023

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.

Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 02, 2022

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.

Journal: International journal of molecular sciences

Published: October 13, 2021

Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function.

Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function.

Journal: Frontiers in immunology

Published: August 14, 2020

DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

Journal: Methods in enzymology

Published: March 18, 2020

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: October 29, 2019

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

Journal: Open biology

Published: October 09, 2019

CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.

CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.

Journal: European journal of immunology

Published: July 15, 2019

TdIF1: a putative oncogene in NSCLC tumor progression.

TdIF1: a putative oncogene in NSCLC tumor progression.

Journal: Signal transduction and targeted therapy

Published: August 01, 2018

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Journal: Oncoimmunology

Published: April 18, 2018

Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Journal: Oncotarget

Published: October 25, 2017

Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein.

Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein.

Journal: The Journal of pharmacology and experimental therapeutics

Published: March 24, 2017

Showing 1-12 of 42

Last Updated: 09/26/2026